United States - English - NLM (National Library of Medicine)

novartis vaccines and diagnostics ltd - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) (unii: k9p8pva2ug) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) - unii:k9p8pva2ug) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for immunization of persons 4 years of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. influenza a (h1n1) 2009 monovalent vaccine should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), or to any component of influenza a (h1n1) 2009 monovalent vaccine, or who has had a life-threatening reaction to previous influenza vaccinations [see description (11)]. novartis’ influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluvirin) are manufactured by the same process. available information for fluvirin is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluvirin. it is also not known whether influenza a (h1n1) 2009 monovalent vaccine or fluvirin can cause fetal harm when administered to

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - bordetella bronchiseptica; canine parainfluenza virus - misc. vaccines or anti sera - bordetella bronchiseptica vaccine-microbial active 0.0 undefined; canine parainfluenza virus vaccine-viral active 0.0 undefined - immunotherapy - dog - over 4 weeks old | puppy - kennel cough | infectious tracheobronchitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - aluminium hydroxide; bordetella bronchiseptica (inactivated cell free extract; canine parainfluenza virus - inactivated - misc. vaccines or anti sera - aluminium hydroxide mineral-aluminium-base active 3.0 mg/do; bordetella bronchiseptica (inactivated cell free extract vaccine-microbial active 0.05 ug/do; canine parainfluenza virus - inactivated vaccine-viral active 0.0 undefined - immunotherapy - dog - with exclusions see label - bordetella bronchiseptica | canine parainfluenza | canine cough syndrome | infectious tracheobronchitis

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine parainfluenza; leptospira icterohaemorrhagiae antigen; canine adeno virus type 2; canine coronavirus vaccine - antigen; canine distemper virus; canine parvo virus - misc. vaccines or anti sera - canine parainfluenza vaccine active 0.0 undefined; leptospira icterohaemorrhagiae antigen vaccine-antigen active 0.0 undefined; canine adeno virus type 2 vaccine-viral active 0.0 undefined; canine coronavirus vaccine - antigen vaccine-viral active 0.0 undefined; canine distemper virus vaccine-viral active 0.0 undefined; canine parvo virus vaccine-viral active 0.0 undefined - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - suspension - excipient ingredients: magnesium chloride hexahydrate; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; water for injections; potassium chloride; calcium chloride dihydrate; sodium chloride - for the prevention of influenza caused by influenza virus, types a and b.,for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.,influvac tetra is indicated in adults and children from 6 months of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - suspension - excipient ingredients: magnesium chloride hexahydrate; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; water for injections; potassium chloride; calcium chloride dihydrate; sodium chloride - for the prevention of influenza caused by influenza virus, types a and b.,for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.,influvac tetra is indicated in adults and children from 6 months of age and older.